

***Amendments***

***In the Specification:***

*Please replace the paragraph beginning on page 1, line 8 with the following two paragraphs:*

B/

This application claims priority to Provisional Appl. No. 60/171,312, filed December 21, 1999 (147.00 US), which is incorporated herein by reference; and is a continuation in part (CIP) of International Appl. No. PCT/US00/17842, filed June 28, 2000, which published in English under PCT Article 21(2) (134.40 PC); and is a CIP of Appl. No. 09/017,743, filed February 3, 1998 (80.50 US); and is a CIP of Appl. No. 09/017,524, filed February 3, 1998 (50.91 US); and is a CIP of Appl. No. 08/454,033, filed May 26, 1995 (58.50 US); and is a CIP of Appl. No. 08/347,610, filed December 1, 1994 (50.50 US); and is a CIP of Appl. No. 08/344,824, filed November 23, 1994 (80.10 US); and is a CIP of Appl. No. 08/205,713, filed March 4, 1994 (58.30 US); said PCT/US00/17842 (134.40 PC) claims priority to Provisional Application No. 60/141,422, filed June 29, 1999; said Appl. No. 09/017,743 (80.50 US) is a CIP of Appl. No. 08/590,298, filed January 23, 1996, abandoned (80.30 US); said Appl. No. 09/017,524 (50.91 US) is a CIP of Appl. No. 08/589,107, filed January 23, 1996, abandoned (50.70 US); said Appl. No. 08/347,610 (50.50 US) is a CIP of Appl. No. 08/159,339, filed November 29, 1993, U.S. Patent No. 6,037,135 (50.30 US), which is a CIP of Appl. No. 08/103,396, filed August 6, 1993, abandoned (50.20 US), which is a CIP of Appl. No. 08/027,746, filed March 5, 1993, abandoned (50.10 US), which is a CIP of Appl. No. 07/926,666, filed August 8, 1992, abandoned (50.00 US); said Appl. No. 08/344,824 (80.10 US)

is a CIP of Appl. No. 08/278,634, filed July 21, 1994, abandoned (80.00 US); said Appl. No. 08/205,713 (58.30 US) is a CIP of Appl. No. 08/159,184, filed November 29, 1993, abandoned (58.20 US), which is a CIP of Appl. No. 08/073,205, filed June 4, 1993, abandoned (58.10 US), which is a CIP of Appl. No. 08/027,146, filed March 5, 1993, abandoned (58.00 US).

This application is related to U.S.S.N. 09/189,702, filed 11/10/98, which is a CIP of U.S.S.N. 08/205,713 filed 3/4/94, which is a CIP of abandoned U.S.S.N. 08/159,184 filed 11/29/93, which is a CIP of abandoned U.S.S.N. 08/073,205 filed 6/4/93 which is a CIP of abandoned U.S.S.N. 08/027,146 filed 3/5/93. The present application is also related to U.S.S.N. 09/226,775, which is a CIP of abandoned U.S.S.N. 08/815,396, which claims benefit of abandoned U.S.S.N. 60/013,113. Furthermore, the present application is related to U.S.S.N. 09/017,735, which is a CIP of abandoned U.S.S.N. 08/589,108; U.S.S.N. 08/454,033; and U.S.S.N. 08/349,177. The present application is also related to U.S.S.N. 09/017,524, U.S.S.N. 08/821,739, which claims benefit of abandoned U.S.S.N. 60/013,833; and U.S.S.N. 08/347,610, which is a CIP of U.S.S.N. 08/159,339, which is a CIP of abandoned U.S.S.N. 08/103,396, which is a CIP of abandoned U.S.S.N. 08/027,746, which is a CIP of abandoned U.S.S.N. 07/926,666. The present application is also related to U.S.S.N. 09/017,743, which is a CIP of abandoned U.S.S.N. 08/590,298; and U.S.S.N. 08/452,843, which is a CIP of U.S.S.N. 08/344,824, which is a CIP of abandoned U.S.S.N. 08/278,634. The present application is also related to PCT application 99/12066 filed 5/28/99 which claims benefit of provisional U.S.S.N. 60/087,192, and U.S.S.N. 09/009,953, which is a CIP of abandoned U.S.S.N. 60/036,713 and abandoned U.S.S.N. 60/037,432. In addition, the present application is related to U.S.S.N. 09/098,584, U.S.S.N. 09/239,043, U.S.S.N. 60/117,486, U.S.S.N. 09/350,401, and U.S.S.N. 09/357,737. In addition, the present application is related to U.S. Patent Application entitled

"Inducing Cellular Immune Responses to Carcinoembryonic Antigen Using Peptide and Nucleic Acid Compositions", Attorney Docket No. 018623-014400, filed 12/10/99; U.S. Patent Application entitled "Inducing Cellular Immune Responses to p53 Using Peptide and Nucleic Acid Compositions"; Attorney Docket No. 018623-014500, filed 12/10/99; U.S. Patent Application entitled "Inducing Cellular Immune Responses to MAGE2/3 Using Peptide and Nucleic Acid Compositions", Attorney Docket No. 018623-014600, filed 12/10/99; and U.S. Patent Application entitled "Inducing Cellular Immune Responses to HER2/neu Using Peptide and Nucleic Acid Compositions", Attorney Docket No. 018623-014800, filed 12/10/99. All of the above applications are incorporated herein by reference.

---

*Please replace the paragraph beginning at page 15, line 1 with the following*

*paragraph:*

---

B The term "peptide" is used interchangeably with "oligopeptide" in the present specification to designate a series of residues, typically L-amino acids, connected one to the other, typically by peptide bonds between the  $\alpha$ -amino and carboxyl groups of adjacent amino acids. The preferred CTL-inducing peptides of the invention are less than about 15 residues in length, and are often 13 residues or less in length and usually consist of between about 8 and about 11 residues, preferably 9 or 10 residues. The preferred HTL-inducing oligopeptides are less than about 50 residues in length and usually consist of between about 6 and about 30 residues, more usually between about 12 and 25, and often between about 15 and 20 residues.

---